We provide you with 20 years of free, institutional-grade data for PXMD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PXMD. Explore the full financial landscape of PXMD stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about PXMD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
PaxMedica, Inc.(NASDAQ:PXMD) 
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indi...
Website: https://www.paxmedica.com
Founded: 2018
IPO Price: $5.25 (Aug 26, 2022)
Full Time Employees: 2
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends